
Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target
Aurinia Pharmaceuticals (AUPH) Analyst Ratings
Bulls say
Aurinia Pharmaceuticals is projected to experience substantial revenue growth, with risk-adjusted product revenues expected to rise from $243.7 million in 2025 to $932.3 million by 2033. The company's pipeline also includes aritinercept, which is anticipated to generate risk-adjusted revenue of $15.4 million in 2030, increasing to $281.6 million in 2033, assuming a favorable probability of launch and market penetration. Furthermore, the anticipated positive impact from the 2024 ACR LN guideline is expected to significantly enhance the growth trajectory of Lupkynis beginning in 2027.
Bears say
Aurinia Pharmaceuticals Inc. faces a challenging financial outlook due to limited revenue growth following the launch of LUPKYNIS, as recent reports indicate stagnant sales and high operational costs that may hinder profitability. The ongoing development of AUR200 introduces additional financial risks, as the company may require substantial investment with uncertain timelines for regulatory approval and market entry. Furthermore, competitive pressures in the biopharmaceutical landscape could impede market share capture, thereby negatively impacting overall financial performance.
This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction
Start investing in Aurinia Pharmaceuticals (AUPH)
Order type
Buy in
Order amount
Est. shares
0 shares